Get started
Author

Dipti Talaulikar

Observed names: D Talaulikar, D. TALAULIKAR, D. Talaulikar, D. Talaulikarfi, Talaulikar, Dipti
Observed institutions: Australian National University, Royal College of Pathologists of Australasia, Australian Cancer Research Foundation, Canberra Hospital, Zhengzhou University, First Affiliated Hospital of Zhengzhou University, Act Health, ACT Government
ORCID: 0000-0001-6766-8345
Observed ORCID: 0000-0001-6766-8345
OpenAlex ID: A5046515308
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
2018 · Frank Vari, David Arpon, et al. · Blood · 313
PDF
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
2020 · Jorge J Castillo, Ranjana H Advani, et al. · The Lancet Haematology · 143
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study
2018 · Jorge J. Castillo, Gilad Itchaki, et al. · Blood · 103
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma
2020 · Colm Keane, Soi C. Law, et al. · Blood Advances · 98
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study
2015 · Colm Keane, Frank Vari, et al. · The Lancet Haematology · 93
PDF
The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma
2016 · Colm Keane, Clare Gould, et al. · Clinical Cancer Research · 86
Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial
2020 · Meletios Dimopoulos, Ramon Garcia Sanz, et al. · Blood Advances · 79
PDF
Multiple myeloma: from diagnosis to treatment.
2013 · Renee Eslick, Dipti Talaulikar · PubMed · 71
The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma
2019 · Colm Keane, Joshua Tobin, et al. · European Journal Of Haematology · 61
PDF
Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
2022 · Irene Dogliotti, Cristina Jiménez, et al. · Leukemia · 51
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma
2023 · Katharine L. Lewis, Lasse H. Jakobsen, et al. · Journal of Clinical Oncology · 49
Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas
2008 · Dipti Talaulikar, Ayesha Choudhury, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 41
Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B‐cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance
2019 · Joel C. Wight, Mimi Yue, et al. · British Journal of Haematology · 35
PDF
Health‐related quality of life in chronic coagulation disorders
2006 · D. TALAULIKAR, B. SHADBOLT, et al. · Haemophilia · 35
A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods
2007 · D Talaulikar, J X Gray, et al. · Journal of Clinical Pathology · 32
DeepSNVMiner: a sequence analysis tool to detect emergent, rare mutations in subsets of cell populations
2016 · T. Daniel Andrews, Yogesh Jeelall, et al. · PeerJ · 30
Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
2014 · N. Weber, P. Mollee, et al. · Internal Medicine Journal · 30
Hepatosplenic T ‐cell lymphoma, immunosuppressive agents and biologicals: what are the risks?
2014 · K. Subramaniam, D. Yeung, et al. · Internal Medicine Journal · 30
A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival
2018 · Colm Keane, Joshua Tobin, et al. · Oncotarget · 29
PDF
Bisphosphonate guidelines for treatment and prevention of myeloma bone disease
2017 · Oi Lin Lee, Noemi Horvath, et al. · Internal Medicine Journal · 29
PDF
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance
2019 · Joshua W. D. Tobin, Gabrielle Rule, et al. · Blood Advances · 27
Staging bone marrow in diffuse large B-cell lymphoma: the role of ancillary investigations
2009 · Dipti Talaulikar, Jane E. Dahlstrom · Pathology · 27
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma
2024 · Michael Sargent Binkley, Jamie E. Flerlage, et al. · Journal of Clinical Oncology · 24
Occult bone marrow involvement in patients with diffuse large B-cell lymphoma: results of a pilot study
2007 · Dipti Talaulikar, Jane E. Dahlstrom, et al. · Pathology · 23
Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI)
2009 · Dipti Talaulikar, Bruce Shadbolt, et al. · Journal of Hematology & Oncology · 22
PDF
Works count: 177
Citation count: 2,178
H-index: 23
I10-index: 50
Year
Topic
Type